NASDAQ · AXSM
Axsome Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AXSM: Nov 02, 2026
Axsome Therapeutics, Inc. Common Stock is expected to report earnings on 11/02/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.68. The reported EPS for the same quarter last year was $-0.94.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.68 | $-0.41 | $-0.95 | 8 |
| Dec 2026 | $-0.16 | $0.31 | $-0.91 | 7 |
| Mar 2027 | $-0.29 | $0.08 | $-0.68 | 3 |
| Jun 2027 | $0.24 | $1.06 | $-0.89 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · Zacks- The Motley Fool · Oct 29, 2:20 PM EDTCould Axsome Therapeutics Turn $5,000 Into $50,000 by 2035?Axsome Therapeutics has crushed the market since 2021.
- The Motley Fool · Oct 28, 9:44 AM EDTAxsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp VolatilityAxsome Therapeutics currently demonstrates a stronger revenue profile than Moderna, ultimately surpassing its counterpart in total sales volume for the quarter ended June 2026 despite starting from a considerably lower historical baseline at the very beginning of the ch
- Zacks · Oct 27, 9:00 AM EDTRhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseRhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 26, 9:00 AM EDTWill Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should KnowAxsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- The Motley Fool · Oct 23, 4:05 PM EDT2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks)Axsome Therapeutics should expand its approved lineup while not facing the threat of generic competition through 2036.
- Zacks · Oct 21, 10:00 AM EDTWill Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.
- The Motley Fool · Oct 16, 10:28 AM EDT2 Under-the-Radar Stocks to Buy and HoldAxsome Therapeutics has a deep late-stage pipeline that could eventually lead to much improved financial results.
- Zacks · Oct 13, 9:01 AM EDTCan Nuplazid and Daybue Strengthen Acadia's Growth Prospects?ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.
- The Motley Fool · Oct 12, 11:50 AM EDTWhere Will Axsome Therapeutics Be in 2030 as Auvelity Expands Into Alzheimer's?Axsome sees at least $8 billion in potential peak Auvelity sales.
- Zacks · Oct 9, 9:28 AM EDT4 CNS Drug Stocks Worth Watching This World Mental Health DayAXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
- The Motley Fool · Oct 7, 10:29 PM EDTAxsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?Axsome Therapeutics is seeing massive revenue growth as it expands its footprint in the central nervous system treatment market.
- The Motley Fool · Oct 1, 3:17 PM EDTAxsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Axsome Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.